In the ever-evolving realm of modern medicine, a once-distant dream to conquer disease through genetics has now inched closer to reality. Last Friday, the U.S. Food and Drug Administration approved exa-cel, also known by its brand name Casgevy, the world’s first gene-editing therapy for sickle cell anemia for people aged 12 and over. The decision comes just under a month after the drug’s approval in the UK, where it was approved for both sickle cell anemia and beta thalassemia.
